CanSino's Covid-19 vaccine candidate approved for military use in China

Elias Hubbard
June 29, 2020

Chinese researchers and firms have been allowed to test eight vaccine candidates in humans at home and overseas.

China's Central Military Commission approved the use of the vaccine by the military on June 25 for a period of one year, CanSino said in a filing.

Chinese companies and researchers have been allowed to test eight vaccine candidates in humans at home and overseas, making China a major front-runner in the race to develop a shot against the virus that has killed almost 500,000 people globally.

The company, which is affiliated to state-owned China National Pharmaceutical Group (Sinopharm), said that its COVID-19 candidate vaccine has displayed promising results in early human trials.

CanSino said Ad5-nCoV is now restricted to military use only.

"The Ad5-nCoV is now limited to military use only and its use can not be expanded to a broader vaccination range without the approval of the Logistics Support Department", CanSino said, referring to the Central Military Commission department which approved the military use of the vaccine.

Ad5-nCoV was among the country's leading candidates for coronavirus vaccine for quite some time.

The company's Wuhan-based unit has already developed a shot using the inactivated coronavirus platform and is testing it on human volunteers as part of a Phase 1/2 trial.

More than half of 17 candidate vaccines identified by the World Health Organization (WHO) that are in clinical evaluation involve Chinese companies or institutes.

CanSino added that it can not guarantee the vaccine - which had its phase one and two clinical trials done in China - will ultimately be commercialised.

No vaccine has been approved by any country for commercial use against the disease caused by coronavirus.

In a recent post on WeChat, CNBG claimed that its experimental COVID-19 vaccine, developed from an inactivated version of the novel coronavirus, has been confirmed to be safe and effective.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER